Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CET
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
2016 Cytokinetics Added to Nasdaq Biotechnology Index
2016 CYTOKINETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
2016 CYTOKINETICS INC : Non-Reliance on Previous Financials, Audits or Interim Review..
2016 CYTOKINETICS INC : Other Events (form 8-K)
2016 Cytokinetics Announces New Data Presented at the International Symposium on A..
2016 CYTOKINETICS : Origent Data Sciences and Cytokinetics Present Analyses Demonstra..
2016 CYTOKINETICS INC : Other Events (form 8-K)
2016 Origent Data Sciences and Cytokinetics Present Analyses Demonstrating Baselin..
2016 CYTOKINETICS INC : Change in Directors or Principal Officers (form 8-K)
2016 CYTOKINETICS : Announces Presentations at the International Symposium on ALS/MND
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2016 85,0 M
EBIT 2016 -3,72 M
Net income 2016 -4,65 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 5,05x
Capi. / Sales 2017 10,7x
Capitalization 429 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 18,3 $
Spread / Average Target 73%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Barabari Sharon A. Surrey Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.429
AMGEN, INC.5.79%115 062
GILEAD SCIENCES, INC.-0.84%93 553
CELGENE CORPORATION-2.67%87 334
REGENERON PHARMACEUTIC..-1.23%38 239
ACTELION LTD1.18%23 977
More Results